In April, the FDA approved decabtagene vicleucel (ide-cel) for earlier treatment of relapsed/refractory multiple myleoma.
Ariana Pelosci
Advertisement
Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
Articles by Ariana Pelosci
The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.
Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation.
Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
2
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
3
Value-Based Care Interventions and Management of CKD Progression
4
Defining the Role of Rilzabrutinib in ITP Management
5
